Lyra TherapeuticsLYRA 29 FCF Yield % is -2,628.32 as of Jul. 02, 2026. GuruFocus rates LYRA with a GF Score™ of 29/100 and a GF Value™ of $2.54 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Lyra Therapeutics ranks worse than 99.5% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lyra Therapeutics FCF Yield % Related Terms
Lyra Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Lyra Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lyra Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyra Therapeutics (LYRA) has a FCF Yield % of -2,628.32 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lyra Therapeutics and its competitors. According to the industry distribution chart, Lyra Therapeutics ranks #1407 out of 1414 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Lyra Therapeutics' FCF Yield % too high?
Lyra Therapeutics' current FCF Yield % is -2,628.32. Based on the distribution chart, Lyra Therapeutics ranks #1407 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyra Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' FCF Yield % compare to EVFM and CLSDQ?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #1407 out of 1414 companies for FCF Yield %. This places Lyra Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lyra Therapeutics and its competitors. Lyra Therapeutics's current FCF Yield % is -2,628.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.54, compared to a current price of $0.62 — trading 75.6% below its estimated fair value. The current FCF Yield % is -2,628.32. Lyra Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current FCF Yield % is -2,628.32 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyra Therapeutics (LYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued.
The current stock price of $0.62 is trading 75.6% below its estimated GF Value™ of $2.54.
GuruFocus considers Lyra Therapeutics to be Possible Value Trap.
Key valuation signals for LYRA:
FCF Yield %: -2,628.32
GF Value™: $2.54 vs. price of $0.62 (75.6% below fair value)
No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score
Get the complete analysis for LYRA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
